YEM Search

搜索结果

ERCC3

靶点ID:TCMBANKGE000441

靶点别名:BTF2; GTF2H; RAD25; TFIIH; TTD2; XPB

靶点描述:ERCC excision repair 3, TFIIH core complex helicase subunit

染色体:2

染色体位置:2q14.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:3435

OMIM_Link:133510

Ensembl_Link:ENSG00000163161

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

TCMBANKHE003734	radix tripterygii wilfordii		雷公藤	To expel wind-dampness, relieve swelling, alleviate pain and dredge the meridian passage./Rheumatoid arthritis, rheumatic arthritis, glomerulonephritis, nephropathy syndrome, erythematous lupus, dryness in eyes and mouth, Behcet’s syndrome, psoriasis, eczema, leprosy, scab sore, intractable lichen.		root, leaf and flower

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN036848	triptolide	PG 490; CT0223; Bio2_000315; AKOS015895128; KBio2_005451; BSPBio_001595; NCGC00163411-02; Triptolide; BCPP000033; Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS,8b.beta.)]-; KBio3_000629; N1733; CHEBI:94966; SCHEMBL10028421; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; AC-6084; IDI1_034065; NCGC00163411-01; NSC163062; KBio2_002883; NSC 163062; Bio2_000795; Triptolid; HY-32735; BRD-A13122391-001-01-9; SMR000466307; MLS000759410; Triptolide (9CI); C09204; Triptolide, <i>Tripterygium wilfordii; PG-490; ST51052768; KBio2_000315; Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS,8b.beta.)]-; CS-0286; KBio3_000630; Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid; 38748-32-2; PG490; SMP1_000110; KBioGR_000315; TPL; NCI60_001223; KBioSS_000315	C20H24O6	360.4	CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C
TCMBANKIN057899	arsenicum;arsenic;as		As	74.92159 g/mol	[As]
TCMBANKIN058205	trans-resveratrol	(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene	C14H12O3	228.24 g/mol	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN059684	Vitamin E β-		C29H50O2	430.79	CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746	α-tocopherol		C29H50O2	430.7 g/mol	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000061	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI000088	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	group
TCMBANKDI000166	-	-	Neoplastic Process	disease
TCMBANKDI000432	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases	-	Congenital Abnormality	disease
TCMBANKDI000485	Eye Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI000771	Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of the immune system	Sign or Symptom	phenotype
TCMBANKDI001180	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases	-	Disease or Syndrome	disease
TCMBANKDI001683	-	Abnormality of the nervous system	Finding	phenotype
TCMBANKDI001721	-	Abnormality of head or neck	Finding	phenotype
TCMBANKDI002213	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system	Disease or Syndrome	disease
TCMBANKDI002461	Eye Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI002718	-	-	Finding	phenotype
TCMBANKDI003353	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI003660	-	Abnormality of metabolism/homeostasis; Abnormal cellular phenotype	Finding	phenotype
TCMBANKDI003879	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases	Abnormality of the genitourinary system	Congenital Abnormality	disease
TCMBANKDI004646	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI004728	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases	-	Disease or Syndrome	disease
TCMBANKDI005528	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases	-	Congenital Abnormality	disease
TCMBANKDI007228	-	-	Finding	phenotype
TCMBANKDI007343	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Finding	phenotype
TCMBANKDI007394	Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument	Disease or Syndrome	group
TCMBANKDI007570	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Finding	phenotype
TCMBANKDI007832	Cardiovascular Diseases	-	Disease or Syndrome	phenotype
TCMBANKDI009080	Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of head or neck	Disease or Syndrome	disease
TCMBANKDI009479	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases	Abnormality of head or neck	Anatomical Abnormality	disease
TCMBANKDI009912	Pathological Conditions, Signs and Symptoms	Abnormality of metabolism/homeostasis	Sign or Symptom	phenotype
TCMBANKDI009951	Nutritional and Metabolic Diseases; Musculoskeletal Diseases	Abnormality of the skeletal system	Disease or Syndrome	disease
TCMBANKDI010081	Musculoskeletal Diseases	Abnormality of the skeletal system	Finding	phenotype
TCMBANKDI010538	-	Abnormality of limbs; Abnormality of the skeletal system	Sign or Symptom	phenotype
TCMBANKDI010589	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases	Abnormality of the integument	Disease or Syndrome	disease
TCMBANKDI011000	Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument	Disease or Syndrome	disease
TCMBANKDI011173	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI011730	Eye Diseases; Nervous System Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI012127	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI012157	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	group
TCMBANKDI012650	Cardiovascular Diseases	Abnormality of the integument; Abnormality of the cardiovascular system	Finding	phenotype
TCMBANKDI013148	Respiratory Tract Diseases; Nervous System Diseases	Abnormality of the nervous system; Abnormality of the respiratory system	Disease or Syndrome	disease
TCMBANKDI013599	-	Growth abnormality	Disease or Syndrome	phenotype
TCMBANKDI014132	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI016360	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI016504	Pathological Conditions, Signs and Symptoms	Abnormality of the integument	Finding	phenotype
TCMBANKDI016890	Digestive System Diseases; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI017024	Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI017965	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Finding	phenotype
TCMBANKDI019309	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases	Abnormality of the eye	Congenital Abnormality	disease
TCMBANKDI019597	Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of head or neck	Finding	phenotype
TCMBANKDI019825	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI020449	Skin and Connective Tissue Diseases	Abnormality of the integument	Pathologic Function	phenotype
TCMBANKDI022394	-	-	Laboratory Procedure	phenotype
TCMBANKDI023906	Eye Diseases	Abnormality of the eye	Finding	phenotype
TCMBANKDI024839	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases	-	Disease or Syndrome	disease
TCMBANKDI024846	-	Abnormality of the breast	Finding	phenotype
TCMBANKDI025420	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI026770	Infections; Respiratory Tract Diseases	-	Disease or Syndrome	disease
TCMBANKDI026790	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Stomatognathic Diseases	Abnormality of head or neck; Abnormality of the skeletal system	Congenital Abnormality	disease
TCMBANKDI027156	-	Abnormality of the nervous system	Anatomical Abnormality	disease
TCMBANKDI028565	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases	-	Disease or Syndrome	disease
TCMBANKDI028799	Eye Diseases	-	Disease or Syndrome	disease
TCMBANKDI029520	Mental Disorders	-	Mental or Behavioral Dysfunction	group
TCMBANKDI030540	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI031029	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI031417	Skin and Connective Tissue Diseases	Abnormality of the integument	Sign or Symptom	phenotype
TCMBANKDI031438	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Finding	phenotype
TCMBANKDI031570	-	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease